BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Tables)

3 Months Ended

Mar. 31, 2021

	Three Months Ended March 31,
	2021		2020
Underlying value of Common Stock ($)		7.02		6.21
Exercise price ($)		7.02		6.21
Expected volatility (%)		85.0		85.0
Term of the option (years)		6.11		6.11
Risk-free interest rate (%)		1.17		0.52

	For the Three Months Ended March 31, 2021
	Number of Options			Weighted Average Exercise Price		Aggregate Intrinsic Value

Outstanding at the beginning of period		3,569,766			3.12		12,338
Granted		985,530			7.02
Forfeited		(78,854	)		3.86
Exercised		(12,646	)		1.84
Outstanding at the end of period		4,463,796			3.97		14,612
Exercisable at the end of period		2,135,586
Weighted average remaining contractual life of outstanding options – years as of March 31, 2021		7.91

	Three Months Ended March 31,
	2021		2020
Research and development expenses, net		331		192
General and administrative		199		145
		530		337

Warrant

Issuance Date

Expiration
Date

Exercise
Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

Private Warrants issued to scientific founders (see 2 below)

November 27, 2017

2,974

(*)

less than $0.001.